- Home
- EWCZ vs ELTX Comparison
EWCZ vs ELTX Comparison
Compare EWCZ & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- ELTX
- Stock Information
- Founded
- EWCZ 2004
- ELTX 2011
- Country
- EWCZ United States
- ELTX United States
- Employees
- EWCZ N/A
- ELTX N/A
- Industry
- EWCZ Package Goods/Cosmetics
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- ELTX Health Care
- Exchange
- EWCZ Nasdaq
- ELTX Nasdaq
- Market Cap
- EWCZ 146.9M
- ELTX 121.7M
- IPO Year
- EWCZ 2021
- ELTX N/A
- Fundamental
- Price
- EWCZ $3.57
- ELTX $5.40
- Analyst Decision
- EWCZ Buy
- ELTX Strong Buy
- Analyst Count
- EWCZ 7
- ELTX 2
- Target Price
- EWCZ $5.64
- ELTX $9.50
- AVG Volume (30 Days)
- EWCZ 773.2K
- ELTX 35.5K
- Earning Date
- EWCZ 05-14-2025
- ELTX 05-19-2025
- Dividend Yield
- EWCZ N/A
- ELTX N/A
- EPS Growth
- EWCZ 29.60
- ELTX N/A
- EPS
- EWCZ 0.22
- ELTX N/A
- Revenue
- EWCZ $216,916,000.00
- ELTX N/A
- Revenue This Year
- EWCZ N/A
- ELTX N/A
- Revenue Next Year
- EWCZ $2.69
- ELTX N/A
- P/E Ratio
- EWCZ $16.18
- ELTX N/A
- Revenue Growth
- EWCZ N/A
- ELTX N/A
- 52 Week Low
- EWCZ $2.72
- ELTX $3.34
- 52 Week High
- EWCZ $12.05
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- EWCZ 50.91
- ELTX 48.43
- Support Level
- EWCZ $3.12
- ELTX $4.85
- Resistance Level
- EWCZ $3.42
- ELTX $5.94
- Average True Range (ATR)
- EWCZ 0.21
- ELTX 0.50
- MACD
- EWCZ 0.11
- ELTX 0.14
- Stochastic Oscillator
- EWCZ 85.52
- ELTX 56.45
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.